Acquisition by Andrew Schwendenman of 17775 shares of Replimune subject to Rule 16b-3

REPL Stock  USD 12.50  0.16  1.30%   
About 67 percent of all Replimune's institutional investors are curious in acquiring. The analysis of the overall investor sentiment regarding Replimune Group suggests that many traders are confidant. Replimune's investing sentiment shows overall attitude of investors towards Replimune Group.
  
Filed transaction by Replimune Group Officer: Chief Accounting Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Replimune insider trading alert for acquisition of common stock by Andrew Schwendenman, Officer: Chief Accounting Officer, on 1st of April 2024. This event was filed by Replimune Group with SEC on 2024-04-01. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Replimune's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Replimune's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Replimune Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Replimune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Replimune Fundamental Analysis

We analyze Replimune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Replimune is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Replimune Group Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Replimune stock to make a market-neutral strategy. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics with similar companies.

Peers

Replimune Related Equities

MLYSMineralys Therapeutics,   6.14   
0%
100.0%
AVTEAerovate Therapeutics   1.56   
0%
25.0%
NVCTNuvectis Pharma   1.53   
0%
24.0%
LYRALyra Therapeutics   1.18   
0%
19.0%
UTHRUnited Therapeutics   0.78   
0%
12.0%
GOSSGossamer Bio   0.48   
0%
7.0%
PTGXProtagonist Therapeutics   0.25   
0%
4.0%
ASNDAscendis Pharma   0.22   
0%
3.0%
MRUSMerus BV   0.07   
0%
1.0%
KRONKronos Bio     
1.0%
0%
CRNXCrinetics Pharmaceuticals   0.04   
1.0%
0%
KURAKura Oncology   0.68   
11.0%
0%
NAMSNewAmsterdam Pharma   0.81   
13.0%
0%
KROSKeros Therapeutics   1.02   
16.0%
0%
SNDXSyndax Pharmaceuticals   1.38   
22.0%
0%
NUVLNuvalent   1.43   
23.0%
0%
PRTCPureTech Health   1.82   
29.0%
0%
VTYXVentyx Biosciences   3.40   
55.0%
0%
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:
Check out Replimune Hype Analysis, Replimune Correlation and Replimune Performance.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Return On Assets
(0.27)
Return On Equity
(0.50)
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.